Patents by Inventor Tate Winter

Tate Winter has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • DRUG DELIVERY METHOD
    Publication number: 20190117745
    Abstract: The present invention relates to a new drug delivery strategy based on prodrug conversion, in which a water-soluble prodrug and its converting enzyme are co-delivered and at a point of administration such as the nasal or buccal mucosa. Enzymatic conversion of the prodrug produces drug in concentrations exceeding the drug's thermodynamic solubility, or saturation level. The supersaturated drug crosses the mucosal membrane quickly, as a result of its high thermodynamic activity, prior to crystallization. This strategy is particularly useful when fast action is required, for example in preventing or responding rapidly to Status Epilepticus (SE) or other central nervous system conditions such as migraine.
    Type: Application
    Filed: October 16, 2018
    Publication date: April 25, 2019
    Applicant: Regents of the University of Minnesota
    Inventors: Ronald A. Siegel, James Cloyd, Tate Winter, Mamta Kapoor
  • Drug delivery method
    Patent number: 10117912
    Abstract: The present invention relates to a new drug delivery strategy based on prodrug conversion, in which a water-soluble prodrug and its converting enzyme are co-delivered and at a point of administration such as the nasal or buccal mucosa. Enzymatic conversion of the prodrug produces drug in concentrations exceeding the drug's thermodynamic solubility, or saturation level. The supersaturated drug crosses the mucosal membrane quickly, as a result of its high thermodynamic activity, prior to crystallization. This strategy is particularly useful when fast action is required, for example in preventing or responding rapidly to Status Epilepticus (SE) or other central nervous system conditions such as migraine.
    Type: Grant
    Filed: July 31, 2014
    Date of Patent: November 6, 2018
    Assignee: Regents of the University of Minnesota
    Inventors: Ronald A. Siegel, James Cloyd, Tate Winter, Mamta Kapoor
  • DRUG DELIVERY METHOD
    Publication number: 20160193305
    Abstract: The present invention relates to a new drug delivery strategy based on prodrug conversion, in which a water-soluble prodrug and its converting enzyme are co-delivered and at a point of administration such as the nasal or buccal mucosa. Enzymatic conversion of the prodrug produces drug in concentrations exceeding the drug's thermodynamic solubility, or saturation level. The supersaturated drug crosses the mucosal membrane quickly, as a result of its high thermodynamic activity, prior to crystallization. This strategy is particularly useful when fast action is required, for example in preventing or responding rapidly to Status Epilepticus (SE) or other central nervous system conditions such as migraine.
    Type: Application
    Filed: July 31, 2014
    Publication date: July 7, 2016
    Applicant: REGENTS OF THE UNIVERSITY OF MINNESOTA
    Inventors: Ronald A. Siegel, James Cloyd, Tate Winter, Mamta Kapoor